Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 3Withdrawn 1No longer available 1Active not recruiting 1

Sponsor Class

INDUSTRY 6OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

pembrolizumab 223Cyclophosphamide 192Radiotherapy 183Nivolumab 181Carboplatin 153Cisplatin 114Paclitaxel 112Dexamethasone 110Radiosurgery 103Magnetic Resonance Spectroscopy 97Surveys and Questionnaires 90Ipilimumab 81Doxorubicin 79Lenalidomide 76Rituximab 75durvalumab 74atezolizumab 72Radiation 72fludarabine 68Standard of Care 68Gemcitabine 68venetoclax 67Specimen Handling 65Etoposide 64Capecitabine 64Bevacizumab 62Oxaliplatin 59Docetaxel 58Biopsy 58Radiotherapy, Intensity-Modulated 56

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × nirogacestat × Clear all
NCT05556798 2026-02-24

A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
9 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡